AbCheck specializes in the discovery and optimization of human therapeutic antibodies, utilizing a versatile technology platform tailored to meet specific needs and desired Target Product Profiles. The company employs a range of advanced technologies, including microfluidics and rabbit mass humanization, alongside state-of-the-art methods such as phage and yeast display libraries. These technologies enable AbCheck to provide high-quality leads for antibody development, demonstrating their capabilities through successful partnerships across the US and Europe.

One of AbCheck's notable innovations is the Single Copy Integration Site Technology, which integrates library-based approaches with microfluidics to enhance antibody discovery. This first-in-class mammalian cell-based library secretion system allows for the creation of expression libraries that are independent of immunization success, thus broadening the applicability of antibody formats. By combining this technology with microfluidics, AbCheck achieves superior screening capabilities, facilitating the identification and optimization of novel antibodies from their Naïve Human Antibody Library and proprietary AbAccel® libraries.

Czechia (Czech Republic)

AbCheck discovers and optimizes human therapeutic antibodies with one of the industry’s most versatile technology platforms. Tailored to specific needs and desired Target Product Profiles, AbCheck leverages both cutting-edge (e.g., microfluidics, rabbit mass humanization) and state-of-the-art (e.g., phage/yeast display libraries) technologies to provide high quality leads. The company has proven its capabilities in multiple partnerships throughout the U.S. and Europe. AbCheck is a wholly-owned subsidiary of Ampersand Biomedicines, a Flagship Pioneering Company.

AbCheck

Company Details